Opinion
Video
Author(s):
A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.
KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition
Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies
Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium